Late-emerging ADHD symptoms and their association with psychotic experiences in a general population-based stimulant-naïve adolescent cohort.
| Audience | Patients, clinicians, healthcare professionals, regulators, and industry researchers. |
| Primary Topic | Clinical and policy analysis: Late-emerging ADHD symptoms and their association with . |
| Source | Read the full source |
Late-emerging ADHD symptoms and their association with psychotic experiences in a general population-based stimulant-naïve adolescent cohort.
A structured CED Clinic overview of 3 key developments in cannabis regulation, market milestones, and scientific research.
| Post Type | Cannabis News & Regulatory Digest using canonical CED layout |
| Items Reviewed | 3 verified updates |
| Primary Dates | October 10, 2026 |
| Related Reading | 3 verified live CED Clinic internal links |
| Update 1 | White matter signatures of addiction (Nkrumah et al., Translational psychiatry) [DOI: 10.1038/s41398-026-04491-8 | PMID: 42855476] |
| Update 2 | Rate and correlates of early (Hall et al., Journal of substance use and addiction treatment) [DOI: 10.1016/j.josat.2026.210106 | PMID: 42735755] |
| Update 3 | Late-emerging ADHD symptoms and their (Nakajima et al., Schizophrenia research) [DOI: 10.1016/j.schres.2026.09.018 | PMID: 42753480] |
This curated cannabis news & regulatory digest brings together 3 key developments across policy movements, regulatory milestones, and public health communications. Reviewing these distinct updates side by side clarifies emerging patterns while preserving the specific clinical context of each report.
Examining these developments concurrently helps clinicians, patients, and families trace the broader trajectory of the field while grounding practical decisions in verified primary data.
Title & Source: White matter signatures of addiction diverge across opioids, cannabis and nicotine and predict impulsive choice in cannabis dependence. (Translational psychiatry, 2026Oct09)
Lead Authors & Identifiers: Richard O Nkrumah, Lea Wetzel, Justin Böhmer, Katharina Eidenmueller et al.. | Primary Record: DOI: 10.1038/s41398-026-04491-8 | PMID: 42855476 Content lane: Research Brief.
Investigational Focus: This was a cross-sectional dual-centre diffusion MRI study comparing 87 people with substance use disorders, 48 with cannabis dependence, 16 with opioid dependence, and 23 with nicotine dependence, against 53 nonsmoking healthy controls. The question was whether white matter microstructure differs by substance and whether those differences relate to impulsive choice in cannabis dependence.
Key Findings & Primary Data: Cannabis dependence and opioid dependence showed convergent white matter abnormalities, with reduced fractional anisotropy and increased mean diffusivity and orientation dispersion across fronto-temporo-parietal and limbic tracts, including the superior longitudinal fasciculus, arcuate fasciculus, cingulum, and middle longitudinal fasciculus. Nicotine dependence showed more limited changes, mainly in mean diffusivity and in anterior and callosal white matter. In cannabis dependence, higher middle longitudinal fasciculus orientation dispersion correlated with steeper delay discounting, r = 0.41, p = 0.011, and the indirect effect was seen only in daily users.
Clinical Guidance: This supports asking about impulsive decision-making, daily use, and functional consequences when cannabis dependence is present. It also gives a biologic rationale for counseling patients that heavier, daily use may track with more measurable cognitive-control burden.
Study Boundaries: The study is cross-sectional, so it cannot establish direction of effect. The sample is modest, especially within the opioid and nicotine groups, which limits subgroup certainty.
Title & Source: Rate and correlates of early discontinuation from Veterans Health Administration intensive outpatient substance use treatment programs. (Journal of substance use and addiction treatment, 2026Dec)
Lead Authors & Identifiers: Rebecca E Sistad Hall, Hildi J Hagedorn, Andrea Cutting, Brittany L Stevenson et al.. | Primary Record: DOI: 10.1016/j.josat.2026.210106 | PMID: 42735755 Content lane: Evidence Check.
Investigational Focus: This retrospective cohort study used Veterans Health Administration electronic records from five Midwest hospitals and included 546 veterans with substance use disorder who had at least one visit in an intensive outpatient program during fiscal years 2022 and 2023. The question was how often patients discontinue within the first week and which factors predict that early dropout.
Key Findings & Primary Data: Early discontinuation, defined as less than one full week of intensive outpatient treatment, occurred in 12% of the cohort. Veterans with alcohol use disorder were significantly less likely to discontinue early, while older veterans were significantly more likely to discontinue. The cohort was predominantly White, 78.75%, male, 92.12%, with a median age of 48.8 years, and cannabis use disorder was present in 29.49%.
Clinical Guidance: The first week of treatment deserves active outreach, especially for older patients. Patients with alcohol use disorder may have different retention patterns, so program planning should account for diagnosis mix rather than treating all substance use disorders the same.
Study Boundaries: This is retrospective and limited to five Midwest VHA sites, so local program features may influence the dropout rate. The study does not explain why patients left, which limits intervention design.
Title & Source: Late-emerging ADHD symptoms and their association with psychotic experiences in a general population-based stimulant-naïve adolescent cohort. (Schizophrenia research, 2026Nov)
Lead Authors & Identifiers: Naomi Nakajima, Satoshi Yamaguchi, Jordan DeVylder, Mitsuhiro Miyashita et al.. | Primary Record: DOI: 10.1016/j.schres.2026.09.018 | PMID: 42753480 Content lane: Research Brief.
Investigational Focus: This population-based longitudinal study followed 2,245 Tokyo Teen Cohort participants at ages 10, 12, 14, and 16 years. The investigators examined whether parent-reported ADHD symptom trajectories were associated with self-reported psychotic experiences at age 16 in adolescents without reported ADHD pharmacotherapy use and without reported lifetime cannabis use at age 16.
Key Findings & Primary Data: Four trajectories emerged: stable-low in 67.6%, partial-persistent in 13.2%, late-decreasing in 12.3%, and late-emerging in 6.9%. Compared with stable-low, the late-emerging group had higher odds of overall psychotic experiences, aOR 1.93, 95% CI 1.05 to 3.55, and distressing psychotic experiences, aOR 2.06, 95% CI 1.01 to 4.20. The partial-persistent group was associated with non-distressing psychotic experiences, aOR 2.36, 95% CI 1.08 to 5.19.
Clinical Guidance: Late-emerging or worsening attention symptoms in adolescence should trigger a broader psychiatric review, including psychotic experiences, sleep, mood, and trauma. The absence of reported cannabis use in this cohort means the signal is about developmental psychopathology, not cannabis exposure itself.
Study Boundaries: ADHD symptoms were parent-reported and psychotic experiences were self-reported, which can introduce measurement bias. The study is observational, so it cannot determine whether ADHD trajectories cause psychotic experiences or share upstream risk factors.
The imaging paper fits a growing effort to map substance-specific brain signatures rather than treating all addiction biology as the same. For cannabis, the signal here sits in fronto-temporo-parietal and limbic pathways, which are the same networks clinicians think about when patients describe slowed judgment, poor follow-through, or difficulty waiting for rewards.
The veteran retention data matter because early dropout is one of the most common failure points in addiction care. A 12% first-week discontinuation rate is lower than many clinicians expect, which suggests that structure, access, and population mix can change retention substantially, and that early engagement strategies may be worth targeting to older patients.
The adolescent cohort adds a developmental layer. When attention problems emerge later in adolescence, especially after a period of relative stability, it is worth asking about sleep, anxiety, trauma, substance exposure, and early psychotic symptoms, because the symptom pattern may carry more meaning than the total ADHD score alone.
What stands out to me is the pattern, not any single number. Cannabis dependence showed a brain-behavior link in a tract tied to cognitive control and valuation, and that is the kind of finding that matches what patients often describe, more impulsive choices, more difficulty with delay, less room for reflection before action.
The veteran study is a reminder that treatment retention is a clinical variable, not an administrative one. If a patient is older, has multiple comorbidities, or seems ambivalent in the first visit, the first week deserves extra attention, because that is where the drop-off happens.
The adolescent data are a good prompt to widen the lens when attention symptoms appear later rather than earlier. I would not treat late-emerging inattention as a simple ADHD story until I have asked about sleep, mood, trauma, family history, and any perceptual changes that may point to a broader psychiatric picture.
How to Interpret This Cannabis News & Regulatory Digest
These studies sit at the intersection of cannabis exposure, addiction biology, treatment engagement, and psychiatric risk. The useful question is not whether they prove a single causal story, but what they add to screening, counseling, and follow-up.
Three Rules for Critical Reading
1. Separate association from causation
The MRI study links cannabis dependence with white matter differences and delay discounting, but it cannot tell us whether cannabis caused the brain findings or whether preexisting traits increased both risk and use. Read the effect size, r = 0.41, as a meaningful association, not a treatment target.
2. Ask who was actually studied
The veteran cohort was mostly White men, median age 48.8, from five Midwest sites, so the 12% first-week dropout rate may not generalize to every program. The adolescent cohort excluded reported stimulant use and had no reported lifetime cannabis use at age 16, which narrows how far the psychosis findings can be extended.
3. Look for the clinical action point
The most actionable signal is early retention in treatment, especially for older patients, and broader psychiatric screening when ADHD symptoms emerge late in adolescence. Imaging findings matter most when they help explain behavior that changes counseling, monitoring, or referral.
CED Perspective Lens: Eight Viewpoints on These Updates
Why these developments matter across clinical, patient, safety, and policy perspectives
What this means for a patient
If you use cannabis daily and notice more impulsive choices, trouble waiting, or worse follow-through, that pattern has some biologic support in this study. It does not mean brain damage is inevitable, but it does mean your symptoms deserve a serious conversation about dose, frequency, and function.
If you are in treatment for substance use, the first week matters a lot. If attention problems show up later in adolescence, especially with unusual perceptions or distress, that is worth telling a clinician promptly. In clinical practice, evaluating patient factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.
Clinical reading for prescribers and therapists
The imaging signal in cannabis dependence sits in tracts tied to valuation and cognitive control, which fits a counseling frame around delay discounting and real-world decision-making. The association was specific to daily users, so frequency history matters when interpreting symptoms.
The VHA cohort suggests a practical retention target, the first week, especially for older patients. The adolescent cohort supports a broader screen when ADHD symptoms emerge late, including psychotic experiences, sleep disruption, mood symptoms, and trauma exposure. In clinical practice, evaluating clinician factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.
Safety and harm reduction signals
The cannabis MRI study links heavier use with a behavioral marker of impulsivity, which matters for driving, work safety, and adherence to treatment plans. The data do not prove acute intoxication risk, but they support caution when patients report daily use and poor impulse control.
Early dropout from treatment is a safety issue because it leaves withdrawal, relapse, and overdose risk less addressed. In adolescents, late-emerging attention symptoms plus psychotic experiences should prompt earlier evaluation rather than watchful waiting alone. In clinical practice, evaluating safety factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.
What service planners should notice
The VHA study gives a concrete benchmark for program performance, 12% first-week discontinuation across five sites. That kind of number can help clinics compare retention strategies, especially for older patients who may need more outreach or lower-friction entry points.
The imaging and adolescent studies do not justify policy by themselves, but they support funding for early screening, longitudinal follow-up, and integrated behavioral health. Programs that track symptom trajectories may catch risk earlier than one-time intake assessments. In clinical practice, evaluating policy factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.
What the evidence adds to the field
The white matter study contributes a substance-comparison design, which is more informative than single-drug imaging work. The cannabis finding is especially interesting because it ties a tract-level measure to delay discounting, a behavior with clear clinical relevance.
The veteran cohort adds real-world retention data, and the Tokyo Teen Cohort adds developmental timing. Together they point toward a research agenda that links brain measures, symptom trajectories, and treatment engagement rather than studying each in isolation. In clinical practice, evaluating research factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.
Where caution is warranted
The MRI study is small and cross-sectional, so reverse causation and confounding remain open. Daily use may be a marker for severity, not the cause of the white matter pattern or the impulsive choice finding.
The VHA study is limited to one health system region, and the adolescent cohort relies on reported absence of cannabis use and stimulant treatment. Both studies leave room for unmeasured factors that could shift the associations. In clinical practice, evaluating skeptic factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.
What families should watch for
If a teen’s attention problems appear later in adolescence, especially after years of relative stability, it is worth asking about sleep, stress, mood, and unusual perceptions. That pattern deserves a clinical review, even if cannabis use is not reported.
For someone entering substance use treatment, the first week is a vulnerable time. Families can help by making appointments easier to attend, checking in early, and noticing whether older relatives or patients seem to disengage quickly. In clinical practice, evaluating caregiver factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.
Bottom-line clinical takeaway
Cannabis dependence is showing up here as a condition with measurable brain and decision-making correlates, especially in daily users. That does not settle causality, but it does support more careful counseling around frequency, function, and impulsivity.
The treatment and adolescent studies both point to timing, the first week of care and the late-emerging symptom window in teens. Those are the moments when a careful clinician should widen the assessment and tighten follow-up. In clinical practice, evaluating takeaway factors requires assessing individual tolerance, baseline functional capacity, and verifiable product testing rather than generalizing from preliminary reports alone.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Frequently Asked Questions
What is covered in this cannabis news & regulatory digest?
This edition reviews 3 verified developments across cannabis policy, regulatory oversight, and clinical science.
How are stories selected for CED digests?
Stories are curated from official primary sources, government agency dockets, and peer-reviewed journals, focusing on practical relevance for patients and clinicians.
Do preliminary reports establish medical efficacy?
No. Observational reports, preprints, and regulatory filings describe emerging trends and require formal clinical trials before treatment efficacy can be claimed.
How should clinicians use these updates?
Clinicians can use these updates to understand patient questions, stay current with state regulations, and maintain evidence-informed counseling.
Where can readers find Dr. Caplan's clinical insights?
Dr. Caplan provides comprehensive clinical perspectives, patient consultations, and educational resources at CEDclinic.com.
Why are multi-topic digests published instead of single stories?
Digests group related updates together to provide a broader thematic overview while preserving important nuances and methodological limits.
What is the primary role of laboratory testing in cannabis policy?
Laboratory testing verifies cannabinoid potency and screens for harmful contaminants like heavy metals, pesticides, and molds to protect consumer health.
How do state regulatory milestones impact patient access?
Administrative milestones establish the licensing rules, product categories, and retail standards that determine how and where registered patients obtain care.
What precautions should families take with medical cannabis at home?
Families should keep all medical cannabis products securely locked in child-resistant containers and clearly labeled to avoid accidental exposure.
How often does CED Clinic publish clinical and policy updates?
CED Clinic publishes regular morning, afternoon, and evening evidence reviews and news digests to keep the community informed.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
